This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Are You Looking for a Top Momentum Pick? Why Anavex Life Sciences (AVXL) is a Great Choice
by Zacks Equity Research
Does Anavex Life Sciences (AVXL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Are Medical Stocks Lagging Adaptive Biotechnologies (ADPT) This Year?
by Zacks Equity Research
Here is how Adaptive Biotechnologies (ADPT) and Anavex Life Sciences (AVXL) have performed compared to their sector so far this year.
Beat the Market the Zacks Way: Amgen, DRDGOLD, Anavex in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
Anavex Life Sciences Stock Skyrockets 95% in 3 Months: Here's Why
by Zacks Equity Research
AVXL stock soars 95% in three months on positive updates from the development programs of its two clinical candidates, blarcamesine and ANAVEX 3-71.
Best Momentum Stocks to Buy for January 21st
by Zacks Equity Research
CDNA, AVXL and ALNY made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 21, 2025.
New Strong Buy Stocks for January 21st
by Zacks Equity Research
CDNA, ALNY, ICL, AVXL and AA have been added to the Zacks Rank #1 (Strong Buy) List on January 21, 2025.
Here's Why 'Trend' Investors Would Love Betting on Anavex Life Sciences (AVXL)
by Zacks Equity Research
Anavex Life Sciences (AVXL) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Are Medical Stocks Lagging Anavex Life Sciences (AVXL) This Year?
by Zacks Equity Research
Here is how Anavex Life Sciences (AVXL) and AbbVie (ABBV) have performed compared to their sector so far this year.
All You Need to Know About Anavex Life Sciences (AVXL) Rating Upgrade to Buy
by Zacks Equity Research
Anavex Life Sciences (AVXL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Mirum (MIRM) Gets EC Approval for Livmarli Label Expansion
by Zacks Equity Research
The European Commission approves Mirum's (MIRM) Livmarli for the treatment of progressive familial intrahepatic cholestasis in patients three months of age and older.
HilleVax (HLVX) Tanks as Norovirus Vaccine Study in Infants Fails
by Zacks Equity Research
HilleVax's (HLVX) phase IIb NEST-IN1 study evaluating HIL-214 for preventing acute gastroenteritis caused by norovirus infection in infants fails to meet its primary efficacy endpoint. Stock falls.
Anavex Life Sciences (AVXL) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Anavex Life Sciences (AVXL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Protagonist (PTGX) Up 14% on Licensing Deal With Takeda
by Zacks Equity Research
Per the deal, Protagonist (PTGX) will grant exclusive rights to Takeda to market its late-stage rare hematology drug. In return, Takeda will make an upfront payment of $300 million.
Vertex's (VRTX) Non-Opioid Pain Drug Meets Primary Goal
by Zacks Equity Research
Three late-stage studies data show that Vertex's (VRTX) experimental non-opioid drug reduced pain across a 48-hour period. Based on this data, VRTX intends to submit an FDA filing by mid-2024.
GSK Lags Q4 Earnings, Tops Sales, Issues Upbeat '24 Guidance
by Zacks Equity Research
GSK's revenues benefit from strong growth across all segments, especially the Shingles and RSV vaccines. The company also issues fresh 2024 guidance for all its segments.
Wall Street Analysts Believe Anavex Life Sciences (AVXL) Could Rally 530.68%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 530.7% in Anavex Life Sciences (AVXL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
New Strong Buy Stocks for January 31st
by Zacks Equity Research
ADMA, IKT, YPF, AVXL and EKSO have been added to the Zacks Rank #1 (Strong Buy) List on January 31, 2024.
New Strong Buy Stocks for January 26th
by Zacks Equity Research
IKT, EGO, MDB, PD and AVXL have been added to the Zacks Rank #1 (Strong Buy) List on January 26, 2023.
Anavex Life Sciences (AVXL) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
Anavex Life Sciences (AVXL) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
New Strong Buy Stocks for January 24th
by Zacks Equity Research
ADMA, PBPB, YPF, CM and AVXL have been added to the Zacks Rank #1 (Strong Buy) List on January 24, 2023.
Anavex (AVXL): Strong Industry, Solid Earnings Estimate Revisions
by Zacks Equity Research
Anavex (AVXL) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
5 Small-Cap Stocks to Play the January Effect
by Sweta Killa
Anavex Life Sciences (AVXL), Peakstone Realty Trust (PKST), AC Immune (ACIU), Getaround (GETR) and Akoya Biosciences (AKYA) could be solid picks to play the January Effect.
Anavex (AVXL) Falls 35% on Mixed Rett Syndrome Study Results
by Zacks Equity Research
Anavex (AVXL) falls 35% on mixed results from the mid to late-stage study of 30 mg ANAVEX2-73 for the treatment of pediatric Rett Syndrome patients aged 5-17 years.
Anavex (AVXL) Rises as CHMP Deems Blarcamesine Eligible for MAA
by Zacks Equity Research
The CHMP agrees that Anavex's (AVXL) blarcamesine for Alzheimer's disease is eligible for submission for a Union Marketing Authorisation in the EU. Shares rise.
Does Anavex Life Sciences (AVXL) Have the Potential to Rally 401.47% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 401.5% in Anavex Life Sciences (AVXL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.